$ATNM

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.

NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research.

NEW YORK, May 25, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. ATNM between October 31, 2022 and August 2, 2024, both dates inclusive ( the "Class Period" ) , of the important May 27, 2025 ...

NEW YORK, May 20, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP notifies investors of the approaching May 27, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Actinium Pharmaceuticals, Inc. ( "Actinium" ...

NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. ATNM between October 31, 2022 and August 2, 2024, both dates inclusive ( the "Class Period" ) , of the important May 26, 2025 ...

NEW YORK, May 15, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. ATNM. Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...